Inclusion Criteria:

- Signed Informed Consent Form

- Age ≥ 18 years

- Metastatic melanoma (Stage IV)

- Histologically confirmed malignant melanoma with measurable or non-measurable disease

- Ability and willingness to comply with study and follow-up procedures

Exclusion Criteria:

- Prior treatment for Stage IV disease with chemotherapy or biologic therapy such as
interferon and interleukin-2

- Complete surgical resection or irradiation of all identifiable sites of disease at
randomization

- Radiation therapy within 14 days prior to Day 1

- Prior therapy with bevacizumab, sorafenib, sunitinib, or other vascular endothelial
growth factor (VEGF) pathway-targeted therapy

- Melanoma of ocular origin

- Known central nervous system (CNS) disease/brain metastases (history of brain disease
or active disease)

- Life expectancy of < 12 weeks

- Current, recent, or planned participation in an experimental drug study other than a
Genentech-sponsored bevacizumab cancer study

- Inadequate organ function

- History of other malignancies within 5 years of Day 1, except for tumors with a
negligible risk for metastasis or death, such as adequately controlled basal cell
carcinoma or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix

- Any other diseases, metabolic dysfunction, physical examination finding, or clinical
laboratory finding giving reasonable suspicion of a disease or condition that
contraindicates the use of an investigational drug or that may affect the
interpretation of the results or renders the patient at high risk from treatment
complications

- Inadequately controlled hypertension

- History of hypertensive crisis or hypertensive encephalopathy

- New York Heart Association (NYHA) Class II or greater CHF

- History of myocardial infarction or unstable angina within 6 months prior to Day 1

- History of stroke or transient ischemic attack within 6 months prior to Day 1

- Significant vascular disease (e.g., aortic aneurysm, aortic dissection) or recent
peripheral arterial thrombosis within 6 months prior to Day 1

- History of hemoptysis within 1 month prior to Day 1

- Evidence of bleeding diathesis or significant coagulopathy (in the absence of
therapeutic anticoagulation)

- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
prior to Day 1 or anticipation of need for major surgical procedure during the course
of the study

- Core biopsy or other minor surgical procedure, excluding placement of a vascular
access device, within 7 days prior to Day 1

- History of abdominal fistula or gastrointestinal perforation within 6 months prior to
Day 1

- Serious, non-healing wound, active ulcer, or untreated bone fracture

- Known hypersensitivity to any component of bevacizumab

- Pregnancy (positive pregnancy test) or lactation

- Current, ongoing treatment with full-dose warfarin